Sub-Tenon's Injection of Triamcinolone Acetonide for Choroidal Neovascularization
|
Accession number;06A0036429
|
| Title;Sub-Tenon's Injection of Triamcinolone Acetonide for Choroidal Neovascularization |
| Author;
KIN AYA
(Graduate School of Medicine, Osaka Univ., JPN)
GOMI FUMI
(Graduate School of Medicine, Osaka Univ., JPN)
SAKAGUCHI HIROKAZU
(Graduate School of Medicine, Osaka Univ., JPN)
OSHIMA YUSUKE
(Graduate School of Medicine, Osaka Univ., JPN)
IKUNO YASUSHI
(Graduate School of Medicine, Osaka Univ., JPN)
KAMEI MOTOHIRO
(Graduate School of Medicine, Osaka Univ., JPN)
OJI MASAHITO
(Graduate School of Medicine, Osaka Univ., JPN)
TANO YASUO
(Graduate School of Medicine, Osaka Univ., JPN)
|
Journal Title;Journal of Japanese Ophthalmological Society
|
Journal Code:Z0666A
|
ISSN:0029-0203
|
|
VOL.110;NO.1;PAGE.19-24(2006)
|
| Figure&Table&Reference;FIG.3, TBL.1, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Purpose: To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Method: Sub-Tenon's injection of triamcinolone acetonide was performed in patients (27 eyes) with the subfoveal choroidal neovascularization of AMD and in patients(10 eyes) with PCV, and its efficacy was evaluated. The visual acuity and the exudation from lesions evaluated by fluorescein angiography or optical coherence tomography (OCT) at three months or six months after injection were compared to the baseline values. Results: Visual acuity was maintained in 23 of the 27 eyes(85.0%) with AMD and in 8 of the 10 eyes (80.0%) with PCV at three months after injection. Six months after infusion, the rate declined to 76.0% and 66.7%, respectively. Exudation from lesions had decreased in 10 eyes of 25 eyes (40.0%) with AMD and in 2 eyes of 9 eyes(22.2%) with PCV by six months after injection. Complete suppression of the lesions was observed in seven eyes (18.9%) with relatively small lesions. Conclusion: Sub-Tenon's injection of triamcinolone acetonide is useful as a treatment modality for AMD and PCV. (author abst.) |
|
|
|
Related Articles;
|
|
